ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Pieris receives funding to develop drug for long COVID treatment
June 28, 2021US-based Pieris Pharmaceuticals has received a funding grant to develop PRS-220 to treat post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF), also called post-COVID-19 syndrome pulmonary fibrosis or long COVID. -
Pieris and Genentech sign $1.4bn respiratory and ophthalmology deal
May 27, 2021Pieris Pharmaceuticals and Roche Group subsidiary Genentech have signed a multi-programme research partnership and licence agreement worth approximately $1.42bn to discover, develop and market respiratory and ophthalmology therapies. -
AZ and Pieris link in $2.1bn respiratory deal
May 05, 2017AstraZeneca has hooked up with US group Pieris Pharmaceuticals to develop novel inhaled medicines for respiratory...
Pharma Sources Insight January 2025
